M. Namjoshi

898 total citations
33 papers, 701 citations indexed

About

M. Namjoshi is a scholar working on Psychiatry and Mental health, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Namjoshi has authored 33 papers receiving a total of 701 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Psychiatry and Mental health, 10 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Namjoshi's work include Bipolar Disorder and Treatment (15 papers), Schizophrenia research and treatment (11 papers) and Electroconvulsive Therapy Studies (10 papers). M. Namjoshi is often cited by papers focused on Bipolar Disorder and Treatment (15 papers), Schizophrenia research and treatment (11 papers) and Electroconvulsive Therapy Studies (10 papers). M. Namjoshi collaborates with scholars based in United States, United Kingdom and Switzerland. M. Namjoshi's co-authors include Mauricio Tohen, Don P. Buesching, Alan Breier, Richard C. Risser, Lizheng Shi, Robert W. Baker, T.M. Sanger, Jipan Xie, Eric Q. Wu and Starr L. Grundy and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Affective Disorders.

In The Last Decade

M. Namjoshi

31 papers receiving 653 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Namjoshi United States 13 527 101 78 71 58 33 701
Robin White United States 9 473 0.9× 46 0.5× 72 0.9× 70 1.0× 46 0.8× 13 571
Barbara van Zwieten‐Boot Netherlands 9 187 0.4× 102 1.0× 86 1.1× 65 0.9× 34 0.6× 11 502
Carolin Miltenburger Sweden 16 206 0.4× 44 0.4× 41 0.5× 25 0.4× 24 0.4× 28 759
Minoru Takeshima Japan 11 251 0.5× 39 0.4× 119 1.5× 69 1.0× 20 0.3× 29 433
Patrick Gagnon‐Sanschagrin United States 13 139 0.3× 116 1.1× 46 0.6× 144 2.0× 75 1.3× 42 637
Carole Dembek United States 11 163 0.3× 34 0.3× 26 0.3× 30 0.4× 147 2.5× 42 555
Jarrett W. Richardson United States 14 92 0.2× 141 1.4× 44 0.6× 55 0.8× 47 0.8× 25 577
Cathy MacDonald Canada 16 126 0.2× 9 0.1× 56 0.7× 76 1.1× 302 5.2× 29 836
Rollon Poinsot France 9 143 0.3× 85 0.8× 28 0.4× 115 1.6× 48 0.8× 24 480
Anna Kurowska Poland 10 84 0.2× 179 1.8× 47 0.6× 64 0.9× 67 1.2× 37 582

Countries citing papers authored by M. Namjoshi

Since Specialization
Citations

This map shows the geographic impact of M. Namjoshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Namjoshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Namjoshi more than expected).

Fields of papers citing papers by M. Namjoshi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Namjoshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Namjoshi. The network helps show where M. Namjoshi may publish in the future.

Co-authorship network of co-authors of M. Namjoshi

This figure shows the co-authorship network connecting the top 25 collaborators of M. Namjoshi. A scholar is included among the top collaborators of M. Namjoshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Namjoshi. M. Namjoshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhu, Ling, et al.. (2022). Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States. Journal of Managed Care & Specialty Pharmacy. 28(11-a Suppl). S2–S13. 5 indexed citations
2.
3.
Xie, Jipan, et al.. (2012). Cost-Effectiveness of Denosumab Compared With Zoledronic Acid in Patients With Breast Cancer and Bone Metastases. Clinical Breast Cancer. 12(4). 247–258. 22 indexed citations
4.
5.
Walker, Mark S., Paul J. Miller, M. Namjoshi, et al.. (2012). Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases. Journal of Medical Economics. 16(1). 179–189. 19 indexed citations
6.
Xie, Jipan, M. Namjoshi, Eric Q. Wu, et al.. (2011). Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. Journal of Managed Care Pharmacy. 17(8). 621–643. 48 indexed citations
7.
8.
Yu, Alex, et al.. (2011). Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.. Journal of Clinical Oncology. 29(15_suppl). e15115–e15115. 4 indexed citations
9.
Russo, Patrícia A., Mark W. Smith, & M. Namjoshi. (2005). Health care costs for schizophrenia patients started on olanzapine versus risperidone. American Journal of Health-System Pharmacy. 62(6). 610–615. 4 indexed citations
10.
Zhao, Zhongyun, M. Namjoshi, Beth Barber, et al.. (2004). Economic Outcomes Associated with Switching Individuals with Schizophrenia Between Risperidone and Olanzapine. CNS Drugs. 18(3). 157–164. 7 indexed citations
11.
Shi, Lizheng, et al.. (2004). Improvement of positive and negative syndrome scale cognitive score associated with olanzapine treatment of acute mania. Current Medical Research and Opinion. 20(9). 1371–1376. 17 indexed citations
12.
13.
Namjoshi, M., Richard C. Risser, Lizheng Shi, Mauricio Tohen, & Alan Breier. (2003). Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. Journal of Affective Disorders. 81(3). 223–229. 25 indexed citations
14.
Tohen, Mauricio, Joseph F. Goldberg, Ana González‐Pinto, et al.. (2003). A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania. Archives of General Psychiatry. 60(12). 1218–1218. 167 indexed citations
15.
Russo, Patrícia A., Mark W. Smith, Riad Dirani, M. Namjoshi, & Mauricio Tohen. (2002). Pharmacotherapy patterns in the treatment of bipolar disorder. Bipolar Disorders. 4(6). 366–377. 18 indexed citations
16.
Shi, Lizheng, M. Namjoshi, Gian Gandhi, et al.. (2002). Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. International Clinical Psychopharmacology. 17(5). 227–237. 54 indexed citations
17.
Namjoshi, M.. (2002). Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania Results from a randomized controlled trial. Journal of Affective Disorders. 69(1-3). 109–118. 40 indexed citations
18.
Yurgelun‐Todd, Deborah, Ligen Shi, Bin Zhu, et al.. (2002). Olanzapine vs divalproex: Prospective comparison on self-reported cognitive function in patients with bipolar disorder. European Neuropsychopharmacology. 12. 308–309. 8 indexed citations
19.
Sanger, T.M., et al.. (2001). Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder. The Journal of Clinical Psychiatry. 62(4). 273–281. 78 indexed citations
20.
Namjoshi, M. & Don P. Buesching. (2001). A review of the health-related quality of life literature in bipolar disorder. Quality of Life Research. 10(2). 105–115. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robin White Breakdown of academic impact, for papers by Barbara van Zwieten‐Boot Breakdown of academic impact, for papers by Carolin Miltenburger Breakdown of academic impact, for papers by Minoru Takeshima Breakdown of academic impact, for papers by Patrick Gagnon‐Sanschagrin Breakdown of academic impact, for papers by Carole Dembek Breakdown of academic impact, for papers by Jarrett W. Richardson Breakdown of academic impact, for papers by Cathy MacDonald Breakdown of academic impact, for papers by Rollon Poinsot Breakdown of academic impact, for papers by Anna Kurowska
Rankless by CCL
2026